AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04266392
Drug: [18F]-DCFPyl Ligand
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To assess the performance of \[18F\]-DCFPyl PET with whole-body MRI and multiparametric pelvic/prostate MRI for PCa detection in men with recurrence as determined by biochemical PSA level or evidence on CIM. Results of tracer uptake and MRI image features on whole body PET/MRI and dedicated pelvic/prostate PET/MRI, alone and together, will be correlated and compared to detection of lesions on CIM that usually includes bone scan (BS) and CT scan of the abdomen and pelvis, or PET imaging with F-18 Fluciclovine.In addition, in patients who undergo biopsy when performed as standard of care, we will correlate image features directly with histopathological findings on lesion biopsy to directly demonstrate that 'radiotracer and/or MRI positive' lesions contain tumor cells.
Trial: NCT03831178
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will take 11 capsules of placebo (corn/soy oil blend) for 12-18 weeks (84-126 days), beginning on day 1 of initial cycle of chemotherapy, and continuing for 4-6 cycles of chemotherapy prior to definitive breast surgery. Study will end when subject undergoes breast surgery.
Trial: NCT00600275
Drug: BGT226
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00293813
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for alendronate and placebo for denosumab
Trial: NCT01498744
Drug: Oral Clindamycin
RxNorm normalized name: clindamycin Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Based on our preliminary susceptibility data, oral clindamycin (10mg/kg up to 300 mg, every 8 hours) is the first line of antibiotic. Patients allergic or intolerant to clindamycin will receive oral trimethoprim-sulfamethoxazole \[bactrim\] (5mg/kg trimethoprim up to 160 mg, every 12 hours).
Trial: NCT03979469
Drug: fentanyl, remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive opioid analgesics, such as fentanyl and remifentanil perioperatively
Trial: NCT02140970
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg/kg orally up to a maximum of 400 mg given once at least 15 minutes prior to ureteral stent removal
Trial: NCT02140970
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Similar-tasting and appearing liquid placebo of equal volume to be given once orally at least 15 minutes prior to ureteral stent removal
Trial: NCT04294459
Drug: Acetaminophen (paracetamol) or equivalent
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Tablets~Route of administration: Oral
Trial: NCT04294459
Drug: Methylprednisolone or equivalent
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution~Route of administration: Intravenous
Trial: NCT01413243
Drug: Trichuris suis ova
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trichuris suis ova 2500 eggs every 2 weeks
Trial: NCT00460655
Drug: GSK1358820
FDA approved: no
EMA approved: no
PMDA approved: no
Description: botulinum toxin type A
Trial: NCT00460655
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00128024
Drug: lipid-lowering treatment
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03797066
Drug: ZEPATIER 50Mg-100Mg Tablet
RxNorm normalized name: ZEPATIER 50mg-100mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zepatier 50/100 OD , with addition of Ribavarin in patients with Genotype 1a and 4 with HCV RNA\> 800,000 iu/ml or baseline NS5A resistance.
Trial: NCT00400218
Drug: MK0954A, hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 Weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00855777
Drug: etoricoxib
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etoricoxib 120 mg/day for 3 days
Trial: NCT00855777
Drug: ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ibuprofen 1,800 mg/day for 3 days
Trial: NCT00655928
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline 1 litre intravenous over 12 hours pre-operatively
Trial: NCT03146988
Drug: RGB-02 or Neulasta® (pegfilgrastim)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-filled syringe containing 6 mg RGB-02 or Neulasta® in 0.6 mL, administered as subcutaneous injection into the abdominal area
Trial: NCT00079261
Drug: CHOP regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00079261
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00079261
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04347512
Drug: Hydroxychloroquine and azithromycin treatment arm.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient allocated in this arm receive hydroxychloroquine and azithromycin for 5 days.~For hydroxychloroquine, there is a loading dose of 800 mg per day at D1, followed by 400 mg per day D2-D5.~For azithromycin, there is a loading dose of 500 mg per day at D1, followed by 250 mg per day D2-D5.~Every patient receive as well antibiotic (ceftriaxone 1-2 g per day IV), and standard of care (oxygen therapy, analgesics, antipyretics, heparin, etc).
Trial: NCT00648921
Drug: Zyprexa® Tablets 5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg, single dose fasting
Trial: NCT01014767
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard Arm, Cycle 1: 1 g/m\^2 IV over 1 hour on day 2 and 3~All Arms, Cycles 3 \& 5: 1 g/m\^2 IV over 1 hour on day 2 and 3
Trial: NCT01014767
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cycles 1 \& 2: 25 mg/m²/day IV over 12 hrs on days 1-3
Trial: NCT01014767
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given with Methotrexate as leucovorin rescue at hour 42 given three times on days 1, 15 and 29.
Trial: NCT01014767
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5g/m2 IV over 24 hours with leucovorin rescue at hour 42 given three times on days 1, 15 and 29.
Trial: NCT03198767
Drug: LIK066
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LIK066 50 mg tablets. Open-label, bulk, blister-pack.
Trial: NCT00330707
Drug: Bacillus Calmette Guerin and interferon alpha
RxNorm normalized name: BACILLUS CALMETTE-GUERIN,TICE VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04551963
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsules administered at a dose and frequency as specified in the treatment arm
Trial: NCT02227030
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03425812
Drug: To withdraw NSAIDs therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAIDs therapy will be withdrew after washout period.
Trial: NCT04019743
Drug: CKD-330 16/10mg Tab. 1T and D086 Tab. 1T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral administration under fasting condition
Trial: NCT04019743
Drug: CKD-333 16/10/40mg formulation 1 Tab. 1T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral administration under fasting condition
Trial: NCT04019743
Drug: CKD-333 16/10/40mg formulation 2 Tab. 1T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral administration under fasting condition
Trial: NCT02227030
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02890745
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01132846
Drug: Dopamine
RxNorm normalized name: Dopamine
DrugBank: Dopamine (DB00988)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants randomized to the low dose dopamine arm will receive dopamine of 2ug/kg/min or placebo during the first 72 hours in the trial.
Trial: NCT02831855
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the open-label run-in phase (Day 1 to Week 24), all subjects will receive one tablet open-label tofacitinib MR 11mg orally QD and open-label methotrexate capsule(s) orally every week at prior stabilized dose.~During the double-blind phase, subjects who are randomized to the treatment arm will receive the same dosage of tofacitinib and methotrexate as describe above.
Trial: NCT02831855
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: During the open-label run-in phase (Day 1 to Week 24), all subjects will receive one tablet open-label tofacitinib MR 11mg orally QD and open-label methotrexate capsule(s) orally every week at prior stabilized dose.~During the double-blind phase, subjects who are randomized to the treatment arm will receive the same dosage of tofacitinib and methotrexate as describe above.
Trial: NCT02831855
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the double-blind phase, subjects who are randomized to the comparison arm will receive 11mg QD tofacitinib and the placebo capsules matching for methotrexate.
Trial: NCT02219932
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo
Trial: NCT02540512
Drug: hydrocodone / acetaminophen 5mg/325mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narcotic/NSAID medication used as the standard medical treatment
Trial: NCT02540512
Drug: Placebo Pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pills will be filled with methylcellulose and administered as a placebo for this intervention.
Trial: NCT04098653
Drug: Cyclophosphamide (CY)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
Trial: NCT00163241
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02010593
Drug: Placebo Vaginal Ring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo VR is a flexible, platinum-catalyzed-cured silicone matrix ring, identical to dapivirine Ring-004, containing no active drug.
Trial: NCT02374281
Drug: Glucose sucking
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01098448
Drug: local tetracycline
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: local delivery of tetracycline fibers releasing approximately 1.7 mg/tooth in all pockets \>5mm
Trial: NCT04424459
Drug: opioid withdrawal
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The data retrieved from the patient will be encrypted and there will also be written data or written in binary form. They will be used to create an Excel table which allows me to list the data on D1 then on M + 3 then on M + 6 in order to evaluate the evolution of these data over a time interval of 6 months and this is which will be used as support in my thesis in pharmacy.
Trial: NCT04323280
Drug: NSAID therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAIDS (Ibuprofen or Aspirin) or Glucocorticoid (Prednisone) therapy for 3 weeks with addional colchicine therapy for 3 months
Trial: NCT00070265
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally
Trial: NCT03018535
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Month 2, 4 and 6: Oral Cyclophosphamide (2.0 mg/kg/day) for 30 days
Trial: NCT00956722
Drug: Bovine Colostrum Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine Colostrum Powder (Biogard)
Trial: NCT03116906
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: to be given for a total of up to 15 days
Trial: NCT00912990
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One Intravenous dose
Trial: NCT02531360
Drug: [18F]MNI-815 (MNI-815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All enrolled subjects will undergo an \[18F\]MNI-815 PET imaging visit. As a part of the screening visit, subjects will undergo \[18F\]florbetaben (FBB) PET imaging to determine if they have significant amyloid deposition.
Trial: NCT04505644
Drug: IV saline infusion +Sham patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: received i.v. saline infusion +Sham patch containing no study medication applied at 12 hours after cesarean delivery and removed 24 hours after delivery. A second sham patch containing no study medication applied at 36 hours after cesarean delivery and removed at 48 hours after delivery.
Trial: NCT04704297
Drug: Treatment of Myofascial Pain Syndrome in the low back. This intervention will be based on outcomes of the medications listed below.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: We are testing which of the three arms is superior for the treatment of Myofascial Pain Syndrome of the Low Back. Pain will be measured using a 10 cm visual analogue scale (VAS) at baseline and 30-minutes after treatment.
Trial: NCT04704297
Drug: Evaluation of functional ability using a patient centered functional score known as the Modified Oswestry Disability Index (MODI). The intervention will be based on outcomes of medications below.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evaluation of functional ability using a patient centered functional score known as the MODI. The MODI will be scored at baseline and 30-minutes after treatment.
Trial: NCT04704297
Drug: Following up with participants 60-72 hours after treatment in the Emergency Department. This intervention will be based on outcomes of the medications listed below.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60-72 after treatment in the Emergency Department, a member of the study team will follow up with participants to repeat a measurement of pain and functional ability on VAS and MODI respectively. This will be compared to baseline measurements.
Trial: NCT02141230
Drug: Alli® 60 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants purchasing Alli®
Trial: NCT02373046
Drug: LX4211
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of LX4211 400 mg as 1 × 400-mg tablet Day 1 or Day 9
Trial: NCT02373046
Drug: LX4211
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of LX4211 400 mg as 2 × 200-mg tablets on Day 1 or Day 9
Trial: NCT01224327
Drug: Conserved therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral or intravenous administration
Trial: NCT00324467
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose: 750 mg/m\^2 Administration: IV infusion day 1 over 20-60 minutes Schedule: Cycle 1, 2, 3, 4, 5\*, 6\* (Week 1, 4, 7, 10, 14, 17)~\* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan
Trial: NCT00324467
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose: 50 mg/m\^2 Administration: IV Push day 1 Schedule: Cycle 1, 2, 3, 4, 5\*, 6\* (Week 1, 4, 7, 10, 14, 17)~\* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan
Trial: NCT00324467
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premedication for R-CHOP Dose: 650 mg Route: PO Schedule: Prior to rituximab and then q 4h during rituximab infusion
Trial: NCT00600106
Drug: 1/10 NA/EE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy with 1 mg norethindrone/10 mcg thinyl estradiol (1/10 NA/EE)
Trial: NCT00324467
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premedication for R-ICE Dose: 650 mg Route: PO Schedule: Prior to rituximab and then q 4h during rituximab infusion
Trial: NCT00600106
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg placebo
Trial: NCT00455507
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two placebo tablets orally once daily for 12 weeks
Trial: NCT01701115
Drug: Low Dose (20 mL) Local Anesthetic (Mepivacaine:Bupivacaine)
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01701115
Drug: Control Dose (40 mL) Local Anesthetic (Mepivacaine:Bupivacaine)
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04606576
Drug: ORMD-0801 QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Insulin once per day
Trial: NCT01413360
Drug: High dose vitamin C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C, 3g per day (tid), with meal, per oral with water 100mL
Trial: NCT01334723
Drug: Adherent with 5-alpha-reductase inhibitor (5ARI) therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient with BPH who are adherent to 5ARI therapy (Adherence will be calculated using a medication possession ratio (MPR); 3 MPR threshold values of 70%, 75%, and 80% will be evaluated.)
Trial: NCT01334723
Drug: Non-adherent to 5ARI therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with BPH non-adherent to 5ARI therapy (Adherence will be calculated using a MPR; 3 MPR threshold values of 70%, 75%, and 80% will be evaluated.)
Trial: NCT03263208
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: patients will receive a standard pre-conditioning regime with cyclophosphamide 0.6-0.8g/m2/day IV for 2 days(Day-5 to day-4).
Trial: NCT04615611
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of placebo
Trial: NCT02912026
Drug: IV F901318
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metabolic profile AUC 0 to infinity
Trial: NCT02912026
Drug: Oral F901318
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metabolic profile AUC 0 to infinity
Trial: NCT01226381
Drug: Von Frey electronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This protocol is based on a study of the interaction setron / paracetamol at 4 different levels of plasma concentrations, by repeating the tests at set intervals, while concentrations of setrons down gradually (half-life of 8 to 10 am ) after a single administration. In addition, the interindividual variability of the effects of paracetamol will be studied, and linking with certain genetic polymorphisms reported by the subjects tested
Trial: NCT00003679
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003679
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01524861
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a placebo tablet bis in die for 12 months
Trial: NCT03636906
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose or 2 doses of Placebo administered intramuscularly at Day 31, or at Day 1 and Day 31, or at Day 1 and Day 61, or at Day 31 and Day 121, depending on the vaccination schedule.
Trial: NCT01701362
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules, placebo for pregabalin administered in divided doses twice a day for 15 weeks after randomization
Trial: NCT03006614
Drug: CAP
RxNorm normalized name: CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03006614
Drug: H
RxNorm normalized name: Hb
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02243319
Drug: HGP1201
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02243319
Drug: HGP0904
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01765036
Drug: SonoVue®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An intravenous 4.8 ml SonoVue® bolus injection was administered to each patient during the procedure
Trial: NCT04329728
Drug: AVM0703
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion over \~1 hours
Trial: NCT02497365
Drug: Tobramycin and Cefazolin
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fortified Tobramycin and Cefazolin eye drops
Trial: NCT01026090
Drug: Placebo (for dronedarone)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: film-coated tablet strictly identical in appearance~Oral administration under fed conditions (during breakfast and dinner)
Trial: NCT03147378
Drug: ModraDoc006/r
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with weekly ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets in fed or fasting condition
Trial: NCT02346227
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo consists of 10% lemon (citrus limon) and 10% lime (citrus aurantifolia) in 80% olive oil.~It is administered as a one time (2 puffs) topical spray of 100 microliters on the cervix.